XOMA Corporation is a biotechnology royalty aggregator. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase I and II. The Company has a portfolio of economic rights and royalty payments associated with partnered pre-commercial therapeutic candidates. It also acquires the economics associated with pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The Company has a portfolio of more than 70 assets. Its royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087), a clinical-stage anti-IL-1b product candidate; scalimab (CFZ533); mezagitamab (TAK-079); RZ358; AZD2936, a TIGIT/PD-1 bispecific antibody; MK-4830, and others. The Company’s geographical segments include Europe, United States and Asia Pacific.